You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

689 Results
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    osimertinib - For the treatment of locally advanced (not amenable to curative therapies) or metastatic non-small cell lung cancer (NSCLC) according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
osimertinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2023
Statistical Reports
*/ For the most recent data, refer to the Ontario Cancer Screening Performance Report 2023.
May 2017
Document
Oct 2017
Document
Oct 2017
Document
Oct 2017
Document
Oct 2017
Document
Oct 2017
Document
Oct 2017
Document
Oct 2017
Document
Nov 2017
Document
Nov 2017
Document
Nov 2017

Pages